Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability,The Prostate

当前位置： X-MOL 学术 › Prostate › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
The Prostate ( IF 2.8 ) Pub Date : 2021-09-01 , DOI: 10.1002/pros.24219
Sonam Suman _{1,

2} , Rahul V Parghane _{1,

2} , Amit Joshi _{2,

3} , Kumar Prabhash _{2,

3} , Sanjay Talole _{2,

4} , Sandip Basu _{1,

2}

Affiliation

The aim of present study was to determine and compare the overall response rates, progression-free survival (PFS), overall survival (OS), and clinical toxicity of the combination of 177Lu-PSMA-617 radioligand therapy (PRLT) and abiraterone acetate (AA) versus 177Lu-PSMA-617 PRLT as monotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients.

中文翻译：

联合 177Lu-PSMA-617 PRLT 和醋酸阿比特龙对比 177Lu-PSMA-617 PRLT 单药治疗转移性去势抵抗性前列腺癌：一项比较疗效和持久性的观察性研究

本研究的目的是确定和比较 177Lu-PSMA-617 放射配体治疗 (PRLT) 和醋酸阿比特龙联合治疗的总缓解率、无进展生存期 (PFS)、总生存期 (OS) 和临床毒性。 AA) 与 177Lu-PSMA-617 PRLT 作为转移性去势抵抗性前列腺癌 (mCRPC) 患者的单一疗法。

更新日期：2021-09-23

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>